Clinical trials: Lymphomas,
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma
- Trial name
- NCT01267812
- Testing
- bortezomib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00060294
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Hodgkin Lymphoma Transformed Recurrent
Italian Multicenter Retrospective Observational Study on Transformed Lymphomas
Study purpose is to evaluate treatment outcome and survival in patient with aggressive lymphomas transformed from Follicular Lymphoma.
- Trial name
- FLT-Oss-2015 (NCT02927756)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the…
- Conditions
- Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT04458922
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma
Evaluating Different Doses of Orelabrutinib in MCL
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.
- Trial name
- NCT05978739
- Testing
- Orelabrutinib High dose, Orelabrutinib Low dose
- Where
- 20 sites in China
- Volunteers
- 40 people
- Sponsor
- InnoCare Pharma Inc.
DLBCL
CR-CHOP+X in Previously Untreated DEL
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL…
- Trial name
- NCT06701357
- Testing
- CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma, DLBCL
Split-Dose R-CHOP for Older Adults With DLBCL
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an…
- Conditions
- Diffuse Large B Cell Lymphoma, DLBCL, Cancer
- Trial name
- NCT03943901
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Wisconsin, Madison
Follicular Lymphoma
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine. In recent years, researchers at the Dana-Farber Cancer Institute have discovered that vaccines made from patient's own cancer…
- Trial name
- NCT00487305
- Testing
- Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Large B Cell Lymphoma, Patient Reported Outcome
The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma
Annually some 450 patients are diagnosed with Diffuse Large B-cell Lymphoma (DLBCL), in Denmark. The majority of these patients are cured with immunochemotherapy, but up to 30 % will relapse, pointing to the need for targeted…
- Trial name
- NCT04695366
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Herlev Hospital
Hodgkin's Disease, Lymphoma
Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial
Background: Researchers are greatly interested in knowing more about the long-term effects of various treatments for cancers such as Hodgkin's disease, particularly from those who have lived 20 to 30 years after treatment.
- Trial name
- NCT00924131
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Gathering information about patients with cutaneous T-cell lymphoma over time may help doctors learn more about the disease.
- Trial name
- NCT00430053
- Testing
- gene rearrangement analysis, polymerase chain reaction, proteomic profiling
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma, Multiple Myeloma
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
In the European Union (EU), plerixafor is indicated in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells (HSCs) to the peripheral blood (PB) for collection and…
- Trial name
- NCT01362972
- Volunteers
- 7,801 people
- Sponsor
- Genzyme, a Sanofi Company
Non-hodgkin Lymphoma
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in participants with relapsed or refractory B-Cell NHL.
- Trial name
- NCT03645395
- Testing
- MT-3724
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Molecular Templates, Inc.
Acute Lymphoblastic Leukemia, Nephrotic Syndrome
Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study
To determine the magnitude and rate of bone mass deficits following initiation of glucocorticoid therapy for the treatment of pediatric leukemia, rheumatic conditions and nephrotic syndrome, we propose a 6 year, prospective study…
- Conditions
- Acute Lymphoblastic Leukemia, Nephrotic Syndrome, Rheumatism
- Trial name
- STOPP-CIS (NCT01663129)
- Where
- 12 sites in Canada
- Volunteers
- 406 people
- Sponsor
- Children's Hospital of Eastern Ontario
Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006029
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, vinorelbine tartrate
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 91 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Chronic Lymphocytic Leukemia
Mosunetuzumab for CLL MRD Clearance
The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic…
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
- Trial name
- NCT07052695
- Testing
- Mosunetuzumab, Ibrutinib, Acalabrutinib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Inhye Ahn
Non-Hodgkin Lymphoma, Burkitt Lymphoma
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this…
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- O-ICE (NCT02393157)
- Testing
- Obinutuzumab, Liposomal ARA-C, Ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
- Trial name
- NCT03349281
- Testing
- Pevonedistat, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Julio Barredo, MD
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439123
- Testing
- Capivasertib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.